OnMedica: GPs poorly informed about degenerative eye disease, survey suggests

24 February 2017
Source: OnMedica

Patients with macular degeneration are not getting the help and support they need from their GPs to manage and treat their condition properly, suggests research* published in the online journal BMJ Open. GPs don’t seem to be very well informed, and the lack of timely information from optometrists and eye specialists may be leading to more patients being registered sight

Read more OnMedica: GPs poorly informed about degenerative eye disease, survey suggests

NIHR Signal: Optometrists are cautious, but may be as good as ophthalmologists at monitoring a common cause of blindness

2 September 2016
Source: NIHR

Why was this study needed? Age-related macular degeneration affects more than 600,000 people in the UK and is the leading cause of vision loss. About 10-15% of these people have the wet form of AMD, which untreated can cause vision to deteriorate within days. Treatment involves injection of drugs into the eye to stop the blood vessel growth. However, because

Read more NIHR Signal: Optometrists are cautious, but may be as good as ophthalmologists at monitoring a common cause of blindness

Macular Society’s call for more funding of research into macular degeneration secures leading expert endorsement

28 June 2016
Source: Macular Society

Charity’s landmark report exposing lack of investment in age-related macular degeneration (AMD) is supported by more than 60 of the UK’s foremost sight researchers, ophthalmologists and institutions Situation described as ‘urgent’  It is a disease with devastating and far-reaching consequences for both patients and their families, and the number of diagnoses is on the rise. But age-related macular degeneration (AMD)

Read more Macular Society’s call for more funding of research into macular degeneration secures leading expert endorsement

Guardian: Cheap blindness drug should be made widely available, says WHO

1 June 2016
Source: Guardian

World Health Organisation rejects expensive licensed drug Lucentis to be added to list for all countries in favour of much cheaper Avastin, not yet available in UK. All countries should make available a cheap, unlicensed drug to prevent blindness in older people – one in preference to the expensive licensed version promoted by pharmaceutical companies, a World Health Organisation committee

Read more Guardian: Cheap blindness drug should be made widely available, says WHO

Patients with High-Risk Macular Degeneration Show Improvement with High-Dose Statin Treatment

7 March 2016
Source: Harvard Medical school

A phase I/II clinical trial at Massachusetts Eye and Ear found that some patients taking high doses of atorvastatin (cholesterol-lowering medication) had complete resolution of lipid deposits in the dry form of age-related macular degeneration (AMD). AMD is the leading cause of blindness in the developed world, and though effective treatments are available for the wet AMD, they are currently

Read more Patients with High-Risk Macular Degeneration Show Improvement with High-Dose Statin Treatment

Your Eyes: Better Sight Manual

11 February 2016
Source: EMHF

People often value their eyesight as the most important of the senses. Yet every year many people suffer loss of vision that could have been prevented or treated. This happens for many reasons. Some people believe, if they can see well, that they have healthy eyes. They may not notice a gradual change in their vision. Others believe changes in

Read more Your Eyes: Better Sight Manual
Your Eyes Booklet 26
Your Eyes Booklet 26

Version: 01.16 Download pdf 8.1 MB

Fight for Sight: Global Scan of Research into Macular Disease

5 January 2016
Source: Fight for Sight

Impact of AMD Research Prioritisation Starting to Show In 2013 the UK vision sector got together to find out what those of you affected by eye disease viewed as the top priorities for eye research. Fight for Sight, the UK’s eye research charity has been working hard to track how closely these patient, relative and carer priorities match the research

Read more Fight for Sight: Global Scan of Research into Macular Disease